Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma

摘要: Direct sequencing remains the most widely used method for detection of epidermal growth factor receptor (EGFR) mutations in lung cancer; however, its relatively low sensitivity limits clinical use. The objective this study was to investigate detecting an mutation from peptide nucleic acid-locked acid polymerase chain reaction (PNA-LNA PCR) clamp and Ion Torrent Personal Genome Machine (PGM) techniques compared that by direct sequencing. Furthermore, predictive efficacy EGFR detected PNA-LNA PCR evaluated. mutational status assessed sequencing, clamp, PGM 57 patients with non-small cell cancer (NSCLC). We evaluated on EGFR-TKI treatment 36 advanced NSCLC retrospectively. Compared (16/57, 28.1%), (27/57, 47.4%) (26/57, 45.6%) more mutations. mutant had significantly longer progressive free survival (14.31 vs. 21.61 months, P = 0.003) than wild when tested clamp. However, no difference response rate TKIs (75.0% 82.4%, 0.195) or overall (34.39 44.10 0.422) observed between Our results demonstrate firstly were frequently those may be as a predicative TKI NSCLC.